Skip to content

A single-center, one-arm, open-label clinical study of gp96 injection extracted from placenta in the treatment of amyotrophic lateral sclerosis

A single-center, one-arm, open-label clinical study of gp96 injection extracted from placenta in the treatment of amyotrophic lateral sclerosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062823
Enrollment
Unknown
Registered
2022-08-19
Start date
2022-08-19
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis

Interventions

Sponsors

Boao Evergrande International Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years, gender is not limited; 2. The diagnosis meets the ALS confirmed and proposed diagnosis in the ALS2020 diagnostic standard (Gold Coast standard); 3. The duration of the disease from the onset of the subject to the time of admission = 2 points, and the respiratory function items were >= 3 points; 5. ALSFRS-R decreased by 1-4 points (>= 1 and = 70%; 7. Patients need to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe renal insufficiency: creatinine clearance 3 times the upper limit of normal value, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.; 3. Screening period, acute myocardial infarction or interventional treatment in the past 6 months, heart failure patients (III-IV according to NYHA classification ); 4. Patients with other serious primary diseases of the nervous system, heart, lungs, hematopoietic system or endocrine system and psychosis; 5. Suspected or indeed have a history of alcohol or drug abuse; 6. Pregnant or lactating women, subjects of childbearing age (including male subjects with heterosexual sex and their female partners with reproductive potential) who have pregnancy plans or are unwilling to take effective contraception within 3 months from the beginning of screening to the cessation of the drug; 7. Have participated in other clinical trials within 30 days before screening, or are participating in other clinical trials; 8. The researchers believe that it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Safety evaluation index;efficacy index;

Secondary

MeasureTime frame
Immunological index;

Countries

China

Contacts

Public ContactZhonghua Zhou
15603731789@126.com+86 15903732068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026